BioXcel eases loan covenant, extends financing deadline
BioXcel Therapeutics, Inc. entered into a Twelfth Amendment to its Credit Agreement and Guaranty with lenders administered by Oaktree Fund Administration LLC.
Rhea-AI Filing Summary
BioXcel Therapeutics, Inc. entered into a Twelfth Amendment to its Credit Agreement and Guaranty with lenders administered by Oaktree Fund Administration LLC. The amendment extends the deadline to on or prior to August 21, 2026 for BioXcel to enter definitive agreements for one or more transactions acceptable to the lenders that either repay all loans and other obligations under the Credit Agreement or constitute an alternative capital solutions transaction on terms acceptable to the lenders. The amendment also reduces the Credit Agreement’s minimum liquidity covenant, requiring minimum cash liquidity of $3.0 million instead of $6.25 million under the prior amendment.
Positive
- Lenders agreed to lower the minimum liquidity covenant to $3.0 million, down from $6.25 million, which eases near‑term cash balance requirements.
- The deadline for securing a transaction that repays the credit facility or provides alternative capital was extended to August 21, 2026, giving the company additional time to arrange financing or strategic options.
Negative
- BioXcel must, by August 21, 2026, enter into agreements for a transaction acceptable to lenders that either fully repays all obligations under the Credit Agreement or provides alternative capital, indicating reliance on successful refinancing or capital solutions.
- The requirement that any alternative capital solutions transaction be on terms and conditions acceptable to the lenders gives lenders significant influence over BioXcel’s future financing structure.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Minimum liquidity covenant: $3.0 million
Prior minimum liquidity covenant: $6.25 million
Deadline for qualifying transaction: August 21, 2026
+1 more
4 metrics
Minimum liquidity covenant
$3.0 million
Minimum cash liquidity required under the Twelfth Amendment
Prior minimum liquidity covenant
$6.25 million
Minimum cash liquidity required under the Eleventh Amendment
Deadline for qualifying transaction
August 21, 2026
Date by which definitive agreements must be entered into under the Twelfth Amendment
Original Credit Agreement date
April 19, 2022
Date of the initial Credit Agreement and Guaranty
Key Terms
Credit Agreement and Guaranty, minimum liquidity covenant, alternative capital solutions transaction, subsidiary guarantors, +1 more
5 terms
Credit Agreement and Guaranty financial
"amended the Credit Agreement and Guaranty, dated April 19, 2022"
minimum liquidity covenant financial
"reduce the Credit Agreement’s minimum liquidity covenant to require minimum cash liquidity"
A minimum liquidity covenant is a clause in a loan or bond agreement that requires the borrower to keep a certain amount of cash or easily sold assets on hand, like an agreed emergency fund. It matters to investors because it protects lenders and other creditors by reducing the chance of missed payments; falling below the required level can trigger penalties, default, or demands for extra collateral, which can affect a company’s borrowing costs and equity value.
alternative capital solutions transaction financial
"or (B) is an alternative capital solutions transaction on terms and conditions acceptable"
subsidiary guarantors financial
"certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors"
administrative agent financial
"Oaktree Fund Administration LLC, as administrative agent"
An administrative agent is a bank or financial firm appointed to handle the day-to-day paperwork and communication for a group of lenders on a loan or credit agreement, acting as the central point for collecting payments, distributing funds, monitoring covenants, and sharing information. For investors, the administrative agent matters because it influences how quickly lenders receive updates, how smoothly repayments and waivers are handled, and how effectively the lending group enforces terms — think of it as a property manager coordinating tasks for multiple owners.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BioXcel Therapeutics (BTAI) change in its credit agreement on August 10, 2026?
BioXcel Therapeutics entered a Twelfth Amendment to its Credit Agreement, extending the deadline to secure a qualifying transaction and reducing the minimum liquidity covenant to $3.0 million. The amendment continues to involve Oaktree as administrative agent.
What is the new minimum liquidity covenant for BioXcel Therapeutics (BTAI)?
The amendment lowers BioXcel’s minimum cash liquidity requirement to $3.0 million, compared with $6.25 million under the prior amendment. This change reduces the cash balance the company must maintain under its Credit Agreement.
By when must BioXcel Therapeutics (BTAI) secure a refinancing or capital transaction?
BioXcel must, on or prior to August 21, 2026, enter into definitive agreements for transactions acceptable to the lenders. These transactions must either repay all loans and obligations under the Credit Agreement or provide an alternative capital solution.
Who are the key parties to BioXcel Therapeutics’ amended Credit Agreement?
The borrower is BioXcel Therapeutics, Inc., with certain subsidiaries as subsidiary guarantors, lenders party to the agreement, and Oaktree Fund Administration LLC serving as administrative agent under the Credit Agreement and its Twelfth Amendment.
What options does BioXcel Therapeutics (BTAI) have under the Twelfth Amendment?
BioXcel must pursue one or more lender‑acceptable transactions that either repay all obligations under the Credit Agreement or constitute an alternative capital solutions transaction on terms and conditions acceptable to the lenders.
When was the original Credit Agreement for BioXcel Therapeutics (BTAI) executed?
The Credit Agreement and Guaranty was originally dated April 19, 2022. It has since been amended multiple times, including the Twelfth Amendment described, which adjusts the liquidity covenant and transaction deadline.
AI-generated analysis. How Rhea-AI works. Not financial advice.
